The effect of antiviral substance 6-(2-morpholin-4-yl-ethyl)-6H-indolo [2,3-b]quinoxaline upon biomarkers of inflammation

• Дата: 2015
• Автори: Antonovych, G.V., Zholobak, N.M., Shibinska, M.O., Spivak, M.Ya.
• Формат: Стаття
• Мова: English
• Опубліковано: Інститут молекулярної біології і генетики НАН України 2015
• Назва видання: Вiopolymers and Cell
• Теми: Biomedicine
• Онлайн доступ: http://dspace.nbuv.gov.ua/handle/123456789/152566
• Назва журналу: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Цитувати: The effect of antiviral substance 6-(2-morpholin-4-yl-ethyl)-6H-indolo [2,3-b]quinoxaline upon biomarkers of inflammation / G.V. Antonovych, N.M. Zholobak, M.O. Shibinska, M.Ya. Spivak // Вiopolymers and Cell. — 2015. — Т. 31, № 4. — С. 264-271. — Бібліогр.: 17 назв. — англ.

Aim. To investigate changes in pro-inflammatory status of laboratory rats after introduction of antiviral substances with interferon-inducing action: 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline and tilorone. Methods. MCP-1 content, blood leukocyte counts and functional activity of phagocytes were measures using flow cytometry techniques. Complement content was determined in microtest based upon hemolysis of sensitized erythrocytes. Results. Both oral and intraperitoneal applications of the substances were characterized by an elevation in monocytic counts, potentiated metabolic reserve of phagocytic cells, increased MCP-1 and complement content in serum. In contrast to tilorone, after introduction of 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline substantial raise in circulating neutrophil counts and their phagocytic activity was not determined, while MCP-1 and complement responses were significantly lower compared to reference substance. Conclusion. Although both substances are IFN-inducers with pluripotent immunostimulatory action, the tested derivative was characterized by a less pronounced elevation of complement activity, MCP-1 content and neutrophil counts. This implies that application of 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline can strengthen innate antiviral resistance with minimized risks of potential autoimmunological adverse effects.